Do Traders Think Collegium Pharmaceutical Inc (COLL) Can Keep Climbing Monday?

The market has been high on Collegium Pharmaceutical Inc (COLL) stock recently. COLL gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Collegium Pharmaceutical Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on COLL!

See Full COLL Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With COLL Stock Today?

Collegium Pharmaceutical Inc (COLL) stock is trading at $39.79 as of 12:48 PM on Monday, Mar 18, a rise of $0.70, or 1.79% from the previous closing price of $39.09. The stock has traded between $38.86 and $39.90 so far today. Volume today is less active than usual. So far 138,249 shares have traded compared to average volume of 461,999 shares. To see InvestorsObserver's Sentiment Score for Collegium Pharmaceutical Inc click here.

More About Collegium Pharmaceutical Inc

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol. Click Here to get the full Stock Report for Collegium Pharmaceutical Inc stock.